Abstract
AbstractClozapine has been recently FDA approved and is expected to become very popular because of its efficacy and lack of extrapyramidal side effects. The neuroleptic malignant syndrome (NMS) has already been reported in two cases associated with clozapine use. In this article, we present a case in which a patient receiving clozapine monotherapy developed a complex of symptoms that appeared to be NMS without rigidity. The case meets specific criteria for NMS and the absence of rigidity may be attributable to the anatomic selectivity of clozapine's dopamine blockade.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
